Invention Grant
- Patent Title: Naphthyridines as inhibitors of HPK1
-
Application No.: US15942321Application Date: 2018-03-30
-
Publication No.: US10407424B2Publication Date: 2019-09-10
- Inventor: Bryan Chan , Naomi Rajapaksa , Michael Siu , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Emanuela Gancia , Graham Jones , Blake Daniels , Michael Lainchbury , Andrew Madin , Eileen Seward , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu , Baihua Hu , Aijun Lu , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Malcolm Huestis , Jun Liang , Sushant Malhotra , Rohan Mendonca
- Applicant: Genentech, Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Genentech, Inc.
- Current Assignee: Genentech, Inc.
- Current Assignee Address: US CA South San Francisco
- Agent Zong-Qiang Bill Tian
- Priority: WOPCT/CN2017/078792 20170330; WOPCT/CN2018/076909 20180215
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61K31/55 ; A61P35/00 ; A61K31/444 ; A61K31/4375 ; A61K31/506 ; C07D519/00 ; A61K31/4545 ; A61K31/4725 ; A61K31/5383 ; A61K31/496 ; A61K31/5377 ; A61K31/5025 ; A61K31/551 ; A61K45/06
Abstract:
Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
Public/Granted literature
- US20180282328A1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 Public/Granted day:2018-10-04
Information query
